Acalabrutinib in Combination with ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Study identifier:ACE-CL-002

ClinicalTrials.gov identifier:NCT02157324

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination with ACP-319 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia

Medical condition

Chronic Lymphocytic Leukemia

Phase

Phase 1

Healthy volunteers

No

Study drug

acalabrutinib, ACP-319

Sex

All

Actual Enrollment

12

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 18 Aug 2014
Primary Completion Date: 20 Jul 2020
Estimated Study Completion Date: 31 May 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria